Core Insights - Chipone Technology has successfully established itself as a leading player in the semiconductor IP industry, being recognized as "China's first semiconductor IP stock" after its listing on the STAR Market in August 2020 [1][2] - The company has achieved significant milestones, including being included in the STAR 50 index and successfully completing a refinancing issuance under the "light asset, high R&D investment" recognition standard [1][3] - As of the end of Q1 2025, Chipone's order backlog reached a record high of 2.456 billion yuan, maintaining a high level for six consecutive quarters, indicating strong demand and growth potential [1][3] Company Development - Chipone Technology was founded in 2001 and has evolved from providing standard cell libraries to offering comprehensive chip customization services and semiconductor IP licensing [2] - The company initially aimed for a NASDAQ listing but chose to return to the Chinese capital market, benefiting from the reforms and growth prospects of the STAR Market [2] R&D and Market Position - Chipone ranks first in China and eighth globally in semiconductor IP licensing revenue as of 2024, with a strong focus on high R&D investment, maintaining over 30% of revenue allocated to R&D from 2020 to 2024 [3][4] - The company has successfully developed 5nm system-on-chip (SoC) technology and is executing multiple projects in the 4nm/5nm range, showcasing its advanced design capabilities [3] Strategic Growth and Financing - The recent A-share private placement marks a significant step for Chipone, allowing for more flexible fund allocation towards R&D and innovation, which is crucial for maintaining competitive advantages [4][5] - The company is also exploring mergers and acquisitions to enhance its industry position and foster ecosystem development, leveraging its status as a leading semiconductor IP provider [5][6] AI and Chiplet Technology - The rise of artificial intelligence has created substantial demand for high-performance chips, particularly in the AI ASIC sector, where Chipone has made significant advancements [6][7] - Chipone's neural network processor (NPU) IP has been adopted in 142 AI chip models across various sectors, including servers and automotive, with over 100 million units shipped [6][7] - The company has been proactive in developing Chiplet technology, which allows for modular integration of chips, enhancing performance while balancing costs, particularly in cloud AI and high-end automotive applications [8]

Group 1 - Chip Origin Co., Ltd. (芯原股份) successfully completed a private placement of A-shares, raising a total of 1.807 billion yuan by issuing 24.86 million shares at a price of 72.68 yuan per share [1] - The initial plan was to issue up to 50.09 million shares, indicating that the actual issuance was less than half of the maximum proposed [1] - The private placement involved 11 institutional investors, including major fund management companies and securities firms, with E Fund Management being the largest subscriber, contributing approximately 755 million yuan, accounting for 42% of the total raised [1][2] Group 2 - Chip Origin Co., Ltd. has previously raised a total of approximately 3.67 billion yuan through two rounds of equity financing, with the first round occurring during its IPO in August 2020 [2] - The funds raised from the latest private placement will be primarily allocated to research and development projects in the AIGC and smart mobility sectors, focusing on Chiplet solutions and new generation IP development [2] - The company specializes in providing platform-based, comprehensive, and one-stop chip customization services and semiconductor IP licensing, with a portfolio of various processor IPs and over 1,600 mixed-signal and RF IPs [3] Group 3 - Despite its technological capabilities, the company faces financial challenges, with projected revenues of 2.338 billion yuan and 2.322 billion yuan for 2023 and 2024, respectively, alongside significant R&D expenditures [3] - The company reported a net loss of 296 million yuan in 2023 and is expected to incur a larger loss of 601 million yuan in 2024 [3] - In the first quarter of this year, the company achieved a revenue of 390 million yuan, reflecting a year-on-year growth of 22.49%, but still reported a net loss of 220 million yuan [3]

国泰海通证券股份有限公司 关于芯原微电子（上海）股份有限公司 之 上市保荐书 目 录 三、本次证券发行上市的项目保荐代表人、协办人及项目组其他成员情况 ..... 17 一、发行人基本情况 （一）发行人基本信息 保荐机构（主承销商） 二〇二五年七月 声 明 本保荐机构及其保荐代表人已根据《中华人民共和国公司法》 （以下简称《公 司法》）、《中华人民共和国证券法》等法律法规和中国证券监督管理委员会（以 下简称"中国证监会"）及上海证券交易所的有关规定，诚实守信，勤勉尽责， 严格按照依法制定的业务规则和行业自律规范出具上市保荐书，并保证所出具文 件真实、准确、完整。 如无特殊说明，本上市保荐书中的简称或名词释义与《芯原微电子（上海） 股份有限公司向特定对象发行 A 股股票之募集说明书》一致。 中文名称 芯原微电子（上海）股份有限公司 英文名称 VeriSilicon Microelectronics (Shanghai) Co., Ltd. 法定代表人 Wayne Wei-Ming Dai（戴伟民） 股票上市地 上海证券交易所 股票简称 芯原股份 股票代码 688521.SH 上市时间 2020年8月18日 股本 ...

证券研究报告 | 首次覆盖报告 gszqdatemark 2025 06 11 年 月 日 芯原股份（688521.SH） 国产算力中坚力量，一站式定制化&IP 领军 一站式定制化&IP 领军，潜心研发致力未来。芯原股份主要服务为面向消 费电子、汽车电子、计算机及周边、工业、数据处理、物联网等广泛应用 市场所提供的一站式芯片定制服务（（24 年占比 68%）和半导体 IP 授权服 务（24 年占比 32%），公司 2024 年营收 23.22 亿元，截至 2025 年一季 度末，公司在手订单金额为 24.56 亿元，创公司历史新高，在手订单已连 续六季度保持高位。从新签订单角度，2025 年一季度公司量产业务新签 订单超 2.8 亿元，截至 2025 年一季度末量产业务在手订单超 11.6 亿元， 对公司未来的业务拓展及业绩转化奠定坚实基础。截至 2024 年，公司研 发人员达 1800 人，占比 89.37%，公司注重研发与人才培养，我们看好公 司的研发积累，进一步提升公司的收入水平，并在规模效应下摊薄费用率， 优化公司利润。 自研 ASIC 需求井喷，设计服务行业迎历史机遇。一站式芯片定制服务 是指向客户 ...

从盘面来看，上述5只个股在5月14日开盘后纷纷上涨，出现冲高迹象，随后的股价走势表现不一。其中，芯原股份的盘中 涨幅一度达到7.11%，截至午市休盘，其最新股价为85.44元/股，上涨2.13%。 本报讯 （记者舒娅疆）北京时间5月14日凌晨，国际指数编制公司明晟公司（MSCI）公布了5月份的指数审议结果。MSCI 全球股票指数（ACWI）新纳入30只股票，剔除61只股票，其中MSCI中国指数新纳入芯原股份、百利天恒、惠泰医疗、光线传 媒、海思科5只A股。 从本次被新增纳入指数名单的5家A股公司来看，他们均具备显著经营亮点和发展优势。 海思科是集新药研发、生产制造、推广营销业务于一体的专业化医药公司，凭借在创新药研发、市场表现以及国际化进程 等方面的突出表现，在医药行业中占据了重要地位。截至2024年底，海思科的商业化产品及进入临床试验阶段的1类新药共有 14个，此外，还有处于筛选阶段的项目40余项，涉及麻醉镇痛、呼吸、慢病、肿瘤和自身免疫等领域。 惠泰医疗被认为是国产电生理及血管介入的头部企业。2024年12月份，公司的电生理产品AForcePlusTM导管、 PulstamperTM导管、心脏脉冲电场消融 ...